Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)

Enhances Commercial and Business Development Expertise with the

Appointment of Joseph P. Hagan to its Board of Directors

VICTORIA, British Columbia--(BUSINESS WIRE)--February 8, 2018--Aurinia

Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the

"Company"), a clinical stage biopharmaceutical company focused on the

global immunology market, today announced the appointment of Joseph P.

"Jay" Hagan. to its board of directors. Mr. Hagan is currently the

President and Chief Executive Officer of Regulus Therapeutics.

"Jay brings a wealth of business development and commercial experience

to our Board," said Richard M. Glickman, Chief Executive Officer and

Chairman of the Board of Aurinia. "He has made significant contributions

to the biotechnology industry during his career, and his strategic

expertise will prove extremely valuable in the board room."

Mr. Hagan joined Regulus in January 2016 as Chief Operating Officer,

Principal Financial Officer and Principal Accounting Officer and was

appointed to President and Chief Executive Officer in May 2017. Mr.

Hagan's career includes roles as the Executive Vice President, Chief

Financial Officer and Chief Business Officer of Orexigen Therapeutics,

Inc., Managing Director of Amgen Ventures and head of corporate

development for Amgen Inc. Mr. Hagan has led numerous strategic and

financing transactions including the acquisitions of Immunex and Tularik

and the spinout of Novantrone and Relyspa, as well as many other

business development efforts totaling over $15 billion in value. Before

joining Amgen, Mr. Hagan spent five years in the bioengineering labs at

Genzyme and Advanced Tissue Sciences. Mr. Hagan currently serves on the

board of directors of Zosano Pharma, a publicly traded biotechnology

company. He received an M.B.A. from Northeastern University and a B.S.

in Physiology and Neuroscience from the University of California, San

"Aurinia's commitment to addressing the significant unmet medical need

in lupus nephritis with the promising results in Phase II clinical

studies of voclosporin is highly encouraging for patients suffering from

this debilitating disease," added Jay Hagan. "I look forward to working

together with the other board directors alongside this exceptional

management team as we pursue a successful future for the company."

Aurinia is a clinical stage

biopharmaceutical company focused on developing and commercializing

therapies to treat targeted patient populations that are suffering from

serious diseases with a high unmet medical need. The company is

currently developing voclosporin, an investigational drug, for the

treatment of LN, FSGS, MCD and DES. The company is headquartered in

Victoria, BC and focuses its development efforts globally. For further

information, see our website at www.auriniapharma.com.

Forward Looking Statements

This press release contains

forward-looking statements, including statements related to

voclosporin's promising results in Phase II clinical studies , Aurinia's

corporate strategy and Mr. Hagan's expected impact on Aurinia's

progress. It is possible that such results or conclusions may change

based on further analyses of these data. Words such as "plans,"

"intends," "may," "will," "believe," and similar expressions are

intended to identify forward-looking statements. These forward-looking

statements are based upon Aurinia's current expectations.

Forward-looking statements involve risks and uncertainties. Aurinia's

actual results and the timing of events could differ materially from

those anticipated in such forward-looking statements as a result of

these risks and uncertainties, which include, without limitation, the

risk that Aurinia's analyses, assessment and conclusions of the results

of its clinical studies may change based on further analyses, the risk

that Aurinia will not successfully complete its clinical programs and

the risk that Aurinia's clinical studies for voclosporin may not lead to

regulatory approval. These and other risk factors are discussed under

"Risk Factors" and elsewhere in Aurinia's Annual Information Form for

the year ended December 31, 2016 filed with Canadian securities

authorities and available at www.sedar.com and on Form 40-F with

the U.S. Securities Exchange Commission and available at www.sec.gov,

each as updated by subsequent filings, including filings on Form 6-K.

Aurinia expressly disclaims any obligation or undertaking to release

publicly any updates or revisions to any forward-looking statements

contained herein to reflect any change in Aurinia's expectations with

regard thereto or any change in events, conditions or circumstances on

which any such statements are based, except as required by law.

We seek safe harbor.

Aurinia Pharmaceuticals Inc.

VP, Corporate & Public Affairs

Hippolyte, 212-364-0458